Molecular Targeting and Signal Transduction, 2004 Cancer Treatment and Research Series, Vol. 119

Langue : Anglais

Coordonnateur : Kumar Rakesh

Couverture de l’ouvrage Molecular Targeting and Signal Transduction

Résumé
Sommaire
Commentaire

Our limited understanding of cellular regulatory signal-transduction-networks has been a barrier to progress in improving the overall cure-rate of human cancers. Delineation of the physiologic roles of the specific regulatory signaling components, with known association with metastatic phenotypes, is a highly promising area which will likely provide the next generation of targeted strategies in the future of molecular cancer medicine. These signaling components are likely to be used in diagnosis, prognosis, and as novel targets for therapeutic development.

This book brings together up-to-date summaries by leading cancer researchers on the major principles of cancer cell biology: survival, apoptosis, adhesion, and cell cycle deregulation. It is directed at clinicians and scientists working in the areas of experimental and molecular therapeutics, molecular medicine, translational cancer research, and bio-medical sciences in general.

Biology of the Epidermal Growth Factor Receptor Family.- Integrin Signaling in Cancer.- Regulators of Vascular Endothelial Growth Factor Expression in Cancer.- Integrin-Linked Kinase (ILK) in Combination Molecular Targeting.- P21-Activated Kinase 1: An Emerging Therapeutic Target.- Basis and Importance of SRC as a Target in Cancer.- Therapeutic Targeting of the Receptor Tyrosine Kinase Met.- Nuclear Factor-?B Activation Mediates Cellular Transformation, Proliferation, Invasion Angiogenesis and Metastasis of Cancer.- The P53 Pathway: Targets for the Development of Novel Cancer Therapeutics.- Runx Protein Signaling in Human Cancers.- Signal Transduction Mediated by Cyclin D1: from Mitogens to Cell Proliferation: A Molecular Target with Therapeutic Potential.- Signal Transduction Pathways in BCR-ABL Transformed Cells.- Estrogen Receptors and Anti-Estrogen Therapies.- Targeting Endothelin Axis in Cancer.- km23: A Novel TGF? Signaling Target Altered in Ovarian Cancer.

Describes the key pathways and factors involved in this process. Distinguished leaders in the field discuss the therapeutic compounds and strategies being developed for the treatment of malignant disease